HTDS.US Hard to Treat Diseases Inc
- Market cap
- USD 110K
- P/E
- -
- P/B
- -
- ROE
- 21.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2010.
Is HTDS.US undervalued?
Graham numberThe Graham number of Hard to Treat Diseases Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hard to Treat Diseases Inc fundamental analysis
No fundamental analysis for Hard to Treat Diseases Inc yet.
Hard to Treat Diseases Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hard to Treat Diseases Inc
Hard to Treat Diseases Inc. manufactures, supplies, and exports human vaccines and biological products in China and internationally. The company offers human vaccines, such as recombinant human papillomavirus bivalent, freeze-dried live attenuated hepatitis A, recombinant hepatitis E, meningococcal polysaccharide, 23-valent pneumococcal polysaccharide, varicella, rabies, group ACYW135meningococcal conjugate, inactivated poliomyelitis, enterovirus Type 71, influenza, meningoc…
Full company profileHard to Treat Diseases Inc financial statements
2010 annualized: Fiscal year 2010 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2010, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hard to Treat Diseases Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 1999 | 2009 | 2010 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 71.6K | 5.39M | 4.44M |
| Gross Profit | 17.2K | 1.42M | 1.34M |
| Operating Income | -971K | 622K | 476K |
| Net Income | -1.01M | 622K | 466K |
| Balance Sheet | |||
| Total Assets | 715K | 4.56M | 3.85M |
| Total Liabilities | 934K | 2.79M | 1.66M |
| Shareholders' Equity | -220K | 1.77M | 2.18M |
| Cash & Short-term Investments | 9.66K | 200K | 203K |
| Cash Flow | |||
| Operating Cash Flow | -575K | 656K | 515K |
| Capital Expenditure | 20.4K | 24.2K | 59.2K |
| Ratios | |||
| ROE | - | 35.1% | 21.3% |
| ROA | -141.3% | 13.6% | 12.1% |
| Net Profit Margin | -1,411.5% | 11.5% | 10.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hard to Treat Diseases Inc dividends
Hard to Treat Diseases Inc has not paid dividends in the last 2 fiscal years.
Who owns Hard to Treat Diseases Inc
Ownership data of Hard to Treat Diseases Inc is not available yet.
Hard to Treat Diseases Inc company profile
- Company name
- Hard to Treat Diseases Inc
- Ticker
- HTDS.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 2655 Ulmerton Road, Clearwater, FL, United States, 33762
- Phone
- 86 755 8272 0498
- Website
- mellowhope.com
About Hard to Treat Diseases Inc
Hard to Treat Diseases Inc. manufactures, supplies, and exports human vaccines and biological products in China and internationally. The company offers human vaccines, such as recombinant human papillomavirus bivalent, freeze-dried live attenuated hepatitis A, recombinant hepatitis E, meningococcal polysaccharide, 23-valent pneumococcal polysaccharide, varicella, rabies, group ACYW135meningococcal conjugate, inactivated poliomyelitis, enterovirus Type 71, influenza, meningococcal Group A, C bivalent polysaccharide conjugate, recombinant hepatitis B, poliomyelitis, and pneumococcal polysaccharide conjugate vaccines. It also provides biopharmaceuticals, including recombinant human coagulation factor VIII for injection, insulin aspart injection, cerebroprotein hydrolysate for injection, recombinant human basic fibroblast growth factor, insulin glargine injection, mouse nerve growth factor for injection, trastuzumab injection, bevacizumab injection, adalimumab injection, recombinant human epidermal growth factor eye drop, recombinant human interferon a2b injection, reteplase (rPA ), and levonorgestrel silastic implant products. In addition, the company offers plasma products comprises human coagulation factor IV, human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, and human immunoglobulin (pH4) for intravenous injection; and chemicals that consists of olaparib tablets, enzalutamide soft capsules, and eribulin mesilate injection. The company markets its products through distribution and sales network. Hard to Treat Diseases Inc. is based in Clearwater, Florida.
Hard to Treat Diseases Inc management
2- Shimin YuanChief Executive Officer
- Dr. Ivana GadjanskiCommunication Director